The company is strategically oriented toward increasing exports and developing new products that meet the needs of the demanding foreign market, so in the countries of central and eastern Europe, where it has its branches and companies, it's developing and growing.
European export markets
Belupo employees abroad
Today, apart from Croatia, Belupo operates on 18 European pharmaceutical markets. The drive to conquer new markets remains a priority and the only way to continue to grow. In the next period, our strategic goals are the deeper penetration of CEE and SEE markets, especially the CIS countries, more focus on several new groups and further diversification of the current portfolio. In the global structure of the product portfolio, we are planning a turnaround in terms of developing new products and a stronger involvement of OTC products in the overall sales of the regional as well as the global market.
our strategic goals are further penetrating the CEE and SEE markets, especially the CIS countries
Belups's vision is to become the leading pharmaceutical company in Central and Eastern Europe. Belupo's mission is to keep the health together.
securing competitiveness
Enthusiasm and dedication to work
corporate social responsibility
communication
innovative solutions
With quality as an imperative we create a desirable workplace in a modern organization with open communication that promotes creativity in everything we do.
The development of new products and the increase in sales, both domestically and on 18 European export markets, are the strategic orientation of all 1500 Belupo employees. The growth strategy of the company is achieved through a combination of organic and inorganic growth - with a strong focus on internationalization of business and strengthening of market share in the Republic of Croatia.
Thanks to its position on the market, business approach and behavior, technological capabilities and production potential, Belupo has gained trust of respectable pharmaceutical manufacturers with whom Belupo achieves a diverse and successful co-operation. Among them, Mylan, Pharmathen, Medis, Lupin and Torrent stand out.
Belupo's strength are its employees. Thanks to their enthusiasm, the desire to prove, dedication to work, home loyalty and the balance of experience and youth, Belupo is growing all these years.
About 1500 employees work in Belupo.
Belupo without the skills, knowledge and capabilities of its most educated staff cannot imagine its future. Continuous exchange of experience and acquisition of new knowledge of Belupo's employees on postgraduate studies, seminars, congresses and symposiums across Croatia and Europe is a prerequisite for Belupo's new successes.
The President of the Board is Hrvoje Kolarić and the Board member is Tihomir Heđever. In Supervisory Board are Martina Dalić, Chairman of the Board and members Petar Miladin, Davor Doko, Branka Perković and Željko Dragec. Chairman of the Audit Committee is Davor Doko. Members of the Audit Committee are Martina Dalić and Branka Perković.
The highlights in the career of Hrvoje Kolarić, Master of Pharmacy and Master of Business Administration (MBA, IEDC), Belupo’s Chairman of the Management Board and Podravka’s Management Board Member, include the prestigious post as Director, Niche Products and Business Development, at BMS Pharmaceuticals.
biography>
Tihomir Heđever, M.Econ., was appointed a new reinforcement to the two-man Management Board. Tihomir Heđever joined the company after working at multinational auditors KPMG where he was Senior Manager at the Audit Department.
biography>
Martina Dalić, Ph.D., was appointed new President of Podravka d.d. in January of 2021 and will be appointed Chairwoman of the Supervisory Board in Belupo at the next Shareholders' Meeting of the Company.
biography>
He was employed at the Law Faculty in Zagreb in 1997 as a junior assistant at the Department for Commercial Law and Companies Law.
biography>
He started his professional career in 2000 in Assets Management department at Zagrebačka banka as assistant portfolio manager, where he participated in founding the company for managing investment funds at Zagrebačka banka.
biography>
Mrs. Branka Perković started its career at Podravka in 1980 as legal specialist for labour, property and commercial law. She is member of the Audit Committee.
biography>
In April of 2017, he was elected a member of the Executive Board. That same year he was elected Chairman of Belupo’s Works Council and employees’ representative on Belupo’s Supervisory Board.
biography>
He started his professional career in 2000 in Assets Management department at Zagrebačka banka as assistant portfolio manager, where he participated in founding the company for managing investment funds at Zagrebačka banka.
biography>
Martina Dalić, Ph.D., was appointed new President of Podravka d.d. in January of 2021 and will be appointed Chairwoman of the Supervisory Board in Belupo at the next Shareholders' Meeting of the Company.
biography>
Mrs. Branka Perković started its career at Podravka in 1980 as legal specialist for labour, property and commercial law. She is member of the Audit Committee.
biography>We have been manufacturing drugs since 1971. In 1980 we modernized and expanded production with a factory in Koprivnica. In 1999, a 7,000-square-foot facility is built at world standards. 2004 begins a new cream, fat, lotion and gel factory. In 2005, a microbiological laboratory was built. In the 21st century, development did not stop: a cream and gel factory and new markets were opened. 2015 begins construction, and in 2017 manufacturing in a new solid, semi-liquid and liquid drug factory.
Podravka is starting to prepare for pharmaceutical-chemical production ie creates the prerequisites for entering a new strategic business area
We report on business operations and business events in a timely, transparent and continuous manner. We allow quick and easy access to information of interest to the financial community.
In the Pharmaceuticals segment, revenue of HRK 978,4 million was generated in 2020, which is an increase of 2,2 percent compared to the comparable period in 2019.
